Stock Screener App

무료 - Play StoreApp Store

설치하다 설치하다

ANNX

$3.942.72%-0.11

Annexon Inc (ANNX)

Date: O: H: L: C: Vol:

Annexon Inc 주식(ANNX)의 최신 뉴스

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.

Lantern Pharma Inc. (LTRN) stock price, news, quote and history - Yahoo Finance Australia

Insider Spends US$100k Buying More Shares In Annexon - simplywall.st

After buying shares at a $3.83 average, Annexon (ANNX) CEO Love Douglas holds 390,476 shares. - Stock Titan

Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting - Investing News Network

More than 8 million people have an eye disease that can cause blindness. Annexon will present trial findings. - Stock Titan

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com - Investing.com Nigeria

Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com - Investing.com South Africa

ANNX: Vonaprument's phase III trial in GA shows promise for vision preservation and broad market impact - TradingView

ANNX: Phase III GA study shows strong vision preservation, with high compliance and dual primary endpoints - TradingView

Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com - Investing.com UK

ANNX: Phase III programs in GBS and GA advance toward key data and regulatory milestones, with strong differentiation - TradingView

Annexon at Wells Fargo 21st annual healthcare conference: late-stage push - Investing.com India

Annexon at Wells Fargo 21st annual healthcare conference: late-stage push - Investing.com

Annexon at Wells Fargo 21st annual healthcare conference: late-stage push - Investing.com Canada

Annexon at Wells Fargo 21st annual healthcare conference: late-stage push - Investing.com UK

Annexon to Participate in Upcoming September Investor Conferences - Investing News Network

Annexon to Participate in Upcoming September Investor Conferences - finance.yahoo.com

ANNX Maintained by JP Morgan -- Price Target Raised to $14.00 - GuruFocus

ANNEXON, INC. : JP MORGAN RAISES TARGET PRICE TO $14 FROM $10 - Moomoo

ANNEXON, INC. : JP MORGAN RAISES TARGET PRICE TO $14 FROM $10 - Bitget

What Annexon (ANNX)'s Dual-Endpoint ARCHER II Update Means For Shareholders - Yahoo Finance

Annexon (ANNX): Pipeline Momentum Is Building, but Cash Discipline Still Runs the Story - AlphaStreet

Annexon (ANNX) Quarterly Figures: The Available Earnings Metric Delivers a Beat in the Current Update; Share Response: The Stock Loses 4.55% in the Current Update - Margin Guidance - vinanet.vn

Annexon (ANNX) Quarterly Figures: The Available Earnings Metric Delivers a Beat in the Current Update; Share Response: The Stock Loses 4.55% in the Current Update - One-Time Gain Impact - dars.gov.et

Annexon (ANNX) Q2 2026 Earnings Call Transcript - AOL.com

Annexon, Inc. Stock 12‑Month Price Target Raised to $15.71, Implies 198% Upside - TradingView

Annexon (ANNX) Q2 2026 Earnings Call Transcript - The Globe and Mail

Annexon Reports Inducement Grants to New Employees under Nasdaq Listing Rule 5635(4) - marketscreener.com

Bank of America Corp DE Has $23.60 Million Stock Holdings in Annexon, Inc. $ANNX - MarketBeat

Annexon Inc (ANNX) Stock News Today - TradingKey

Annexon Inc (ANNX) Stock News Today - TradingKey

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

At $5.29, Annexon grants new employees options vesting over four years - Stock Titan

Annexon (ANNX) Adds Dual Primary Endpoint in Phase 3 Trial, Refl - GuruFocus

Annexon (ANNX) Earnings Call zu Q2 2026: ARCHER II erweitert, BLA-Einreichung im Zeitplan - TradingKey

Annexon (ANNX) Q2 2026 Earnings Call: ARCHER II Expanded, BLA Filing on Track - TradingKey

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Barchart.com

What is HC Wainwright's Estimate for Annexon Q3 Earnings? - MarketBeat

Annexon (ANNX) Is Down 6.1% After Dual Endpoint Shift in ARCHER II Trial - What's Changed - Sahm

Annexon (NASDAQ:ANNX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat

ANNX SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus

Annexon (ANNX) Is Down 6.1% After Dual Endpoint Shift in ARCHER II Trial - What's Changed - webull.com

State Street Corp Boosts Annexon Inc (ANNX) Stake by 42% in June Transaction - GuruFocus

A Quick Look at Today's Ratings for Annexon(ANNX.US), With a Forecast Between $8 to $27 - Moomoo

Insider for ANNX (ANNX) plans sale of 2,000 shares after option exercise - Stock Titan

Annexon (ANNX), What Is Behind Its Latest Update? - Yahoo Finance

ANNX와(과) 유사한 종목